Cargando…

Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy

BACKGROUND: Brain metastases (BM) are severe incidents among patients with non-small cell lung cancer (NSCLC) and have been associated with significant morbidity and decreased survival; thus, new methods are required to improve clinical management. Magnetic resonance spectroscopy (MRS) allows noninv...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Congli, Li, Zhengquan, Guo, Dong, Zhang, Zhen, Yu, Jingming, Jiang, Guangdong, Xing, Xiaobo, Ji, Shengjun, Jin, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764647/
https://www.ncbi.nlm.nih.gov/pubmed/33376357
http://dx.doi.org/10.2147/OTT.S286893
_version_ 1783628306160025600
author Jia, Congli
Li, Zhengquan
Guo, Dong
Zhang, Zhen
Yu, Jingming
Jiang, Guangdong
Xing, Xiaobo
Ji, Shengjun
Jin, Feng
author_facet Jia, Congli
Li, Zhengquan
Guo, Dong
Zhang, Zhen
Yu, Jingming
Jiang, Guangdong
Xing, Xiaobo
Ji, Shengjun
Jin, Feng
author_sort Jia, Congli
collection PubMed
description BACKGROUND: Brain metastases (BM) are severe incidents among patients with non-small cell lung cancer (NSCLC) and have been associated with significant morbidity and decreased survival; thus, new methods are required to improve clinical management. Magnetic resonance spectroscopy (MRS) allows noninvasive measurements of biochemical information from tumor tissue, providing clinically useful imaging biomarkers. The primary aim of this study was to explore the application of MRS in the assessment of tumor prognosis after stereotactic radiotherapy in NSCLC patients with BM. PATIENTS AND METHODS: MRS was performed on NSCLC patients attending Qingdao Center Hospital with suspected BM, and 68 patients were included in the survival analysis. The qualitative and quantitative parameters of MRS metabolites, such as choline (Cho), creatine (Cr), and N-acetyl-aspartate (NAA), were recorded. To select a cutoff for MRS metabolite parameters in the tumor and to distinguish patients who had recurrence, we performed an ROC curve analysis. Univariate and multivariate Cox regression analyses were used to assess the association between MRS metabolite parameters and clinical cancer prognosis. RESULTS: The average age was 56 years. A total of 68 NSCLC patients underwent metabolic evaluation with single voxel proton MRS and were selected for retrospective analysis. According to the area under the curve (AUC) to predict recurrence, the MRS metabolite parameters were determined as Cho (AUC=0.550), Cr (AUC=0.415), NAA (AUC=0.524), NAA/Cr (AUC=0.600), Cho/Cr (AUC=0.723), and Cho/NAA (AUC=0.543). Cho and Cr predicted poor survival while Cho/Cr and NAA/Cr predicted improved survival (P<0.05). In the multivariate model with adjustment to establish the potential role of MRS metabolite parameters, Cho/Cr showed a significant association with OS (P=0.009) and PFS (P=0.006) after stereotactic radiotherapy. CONCLUSION: The positive results of this study indicate the predictive value of metabolic characteristics of BM detected with MRS for the outcome after stereotactic radiotherapy.
format Online
Article
Text
id pubmed-7764647
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77646472020-12-28 Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy Jia, Congli Li, Zhengquan Guo, Dong Zhang, Zhen Yu, Jingming Jiang, Guangdong Xing, Xiaobo Ji, Shengjun Jin, Feng Onco Targets Ther Original Research BACKGROUND: Brain metastases (BM) are severe incidents among patients with non-small cell lung cancer (NSCLC) and have been associated with significant morbidity and decreased survival; thus, new methods are required to improve clinical management. Magnetic resonance spectroscopy (MRS) allows noninvasive measurements of biochemical information from tumor tissue, providing clinically useful imaging biomarkers. The primary aim of this study was to explore the application of MRS in the assessment of tumor prognosis after stereotactic radiotherapy in NSCLC patients with BM. PATIENTS AND METHODS: MRS was performed on NSCLC patients attending Qingdao Center Hospital with suspected BM, and 68 patients were included in the survival analysis. The qualitative and quantitative parameters of MRS metabolites, such as choline (Cho), creatine (Cr), and N-acetyl-aspartate (NAA), were recorded. To select a cutoff for MRS metabolite parameters in the tumor and to distinguish patients who had recurrence, we performed an ROC curve analysis. Univariate and multivariate Cox regression analyses were used to assess the association between MRS metabolite parameters and clinical cancer prognosis. RESULTS: The average age was 56 years. A total of 68 NSCLC patients underwent metabolic evaluation with single voxel proton MRS and were selected for retrospective analysis. According to the area under the curve (AUC) to predict recurrence, the MRS metabolite parameters were determined as Cho (AUC=0.550), Cr (AUC=0.415), NAA (AUC=0.524), NAA/Cr (AUC=0.600), Cho/Cr (AUC=0.723), and Cho/NAA (AUC=0.543). Cho and Cr predicted poor survival while Cho/Cr and NAA/Cr predicted improved survival (P<0.05). In the multivariate model with adjustment to establish the potential role of MRS metabolite parameters, Cho/Cr showed a significant association with OS (P=0.009) and PFS (P=0.006) after stereotactic radiotherapy. CONCLUSION: The positive results of this study indicate the predictive value of metabolic characteristics of BM detected with MRS for the outcome after stereotactic radiotherapy. Dove 2020-12-22 /pmc/articles/PMC7764647/ /pubmed/33376357 http://dx.doi.org/10.2147/OTT.S286893 Text en © 2020 Jia et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jia, Congli
Li, Zhengquan
Guo, Dong
Zhang, Zhen
Yu, Jingming
Jiang, Guangdong
Xing, Xiaobo
Ji, Shengjun
Jin, Feng
Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy
title Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy
title_full Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy
title_fullStr Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy
title_full_unstemmed Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy
title_short Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy
title_sort brain metastases of non-small cell lung cancer: magnetic resonance spectroscopy for clinical outcome assessment in patients with stereotactic radiotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764647/
https://www.ncbi.nlm.nih.gov/pubmed/33376357
http://dx.doi.org/10.2147/OTT.S286893
work_keys_str_mv AT jiacongli brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT lizhengquan brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT guodong brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT zhangzhen brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT yujingming brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT jiangguangdong brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT xingxiaobo brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT jishengjun brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy
AT jinfeng brainmetastasesofnonsmallcelllungcancermagneticresonancespectroscopyforclinicaloutcomeassessmentinpatientswithstereotacticradiotherapy